A randomized trial of Plasma-Lyte A and 0.9 % sodium chloride in acute pediatric gastroenteritis by unknown
RESEARCH ARTICLE Open Access
A randomized trial of Plasma-Lyte A and
0.9 % sodium chloride in acute pediatric
gastroenteritis
Coburn H. Allen1*, Ran D. Goldman2, Seema Bhatt3, Harold K. Simon4, Marc H. Gorelick5, Philip R. Spandorfer6,
David M. Spiro7, Sharon E. Mace8, David W. Johnson9, Eric A. Higginbotham1, Hongyan Du10, Brendan J. Smyth11,
Carol R. Schermer10 and Stuart L. Goldstein3
Abstract
Background: Compare the efficacy and safety of Plasma-Lyte A (PLA) versus 0.9 % sodium chloride (NaCl)
intravenous (IV) fluid replacement in children with moderate to severe dehydration secondary to acute
gastroenteritis (AGE).
Methods: Prospective, randomized, double-blind study conducted at eight pediatric emergency departments
(EDs) in the US and Canada (NCT#01234883). The primary outcome measure was serum bicarbonate level at 4 h.
Secondary outcomes included safety and tolerability. The hypothesis was that PLA would be superior to 0.9 %
NaCl in improvement of 4-h bicarbonate. Patients (n = 100) aged ≥6 months to <11 years with AGE-induced
moderate-to-severe dehydration were enrolled. Patients with a baseline bicarbonate level ≤22 mEq/L formed the
modified intent to treat (mITT) group.
Results: At baseline, the treatment groups were comparable except that the PLA group was older. At hour 4, the
PLA group had greater increases in serum bicarbonate from baseline than did the 0.9 % NaCl group (mean ± SD
at 4 h: 18 ± 3.74 vs 18.0 ± 3.67; change from baseline of 1.6 and 0.0, respectively; P = .004). Both treatment groups
received similar fluid volumes. The PLA group had less abdominal pain and better dehydration scores at hour 2
(both P = .03) but not at hour 4 (P = 0.15 and 0.08, respectively). No patient experienced clinically relevant worsening of
laboratory findings or physical examination, and hospital admission rates were similar. One patient in each treatment
group developed hyponatremia. Four patients developed hyperkalemia (PLA:1, 0.9 % NaCl:3).
Conclusion: In comparison with 0.9 % NaCl, PLA for rehydration in children with AGE was well tolerated and led to
more rapid improvement in serum bicarbonate and dehydration score.
Trial registration: NCT#01234883 (Registration Date: November 3, 2010).
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Background
Acute gastroenteritis (AGE) complicated by dehydration
remains a major cause of childhood morbidity and mortal-
ity, requiring significant healthcare expenditure worldwide
[1–3]. Approximately 179 million cases of AGE occur in
the US each year [4–6]. Despite a decrease in positive la-
boratory diagnoses of AGE, likely attributable to rotavirus
vaccination availability since 2006 [7], substantial disease
remains. The fluid loss associated with AGE not only
causes dehydration, but can lead to metabolic acidosis and
electrolyte disturbances [1, 6, 8, 9].
Intravenous fluid therapy (IVT) is the mainstay of
treatment for severe pediatric dehydration, and the re-
quirement for continued IVT is the leading indication
for hospitalization. However, recommendations for IVT
are poorly standardized, and significant controversy ex-
ists as to the optimal fluid for use in children [10, 11]. In
general, isotonic fluids are advised for acute rehydration
with the most commonly administered fluids being
0.9 % sodium chloride (NaCl) and Lactated Ringer’s
(LR) solution [12]. However, 0.9 % NaCl, which contains a
supraphysiologic chloride concentration, can induce
hyperchloremic metabolic acidosis (HCA), which can
exacerbate the low serum bicarbonate levels often associ-
ated with diarrhea and poor perfusion from dehydration
[13]. To prevent HCA, clinicians use LR, but concerns of
hyponatremia due to low sodium concentration limit
its use [12]. Thus, there is a substantial need to further
evaluate alternative isotonic crystalloids as a treatment
for AGE [10].
Plasma-Lyte A (PLA, Baxter Healthcare, Deerfield, IL),
a balanced isotonic crystalloid, contains physiologic so-
dium, chloride, potassium, magnesium, and bicarbonate
precursors in mEq/L: Na 140, K 5, Cl 98, Mg 3, Acetate
27, and gluconate 23, pH 7.4). It is utilized as a source
of water and electrolytes or as an alkalinizing agent. Sev-
eral studies in adults have reported a reduction in the in-
cidence of hyperchloremia and metabolic acidosis with
balanced solutions (eg, LR and PLA) over 0.9 % NaCl
[14–16]. The osmolarity of Plasma-Lyte A is 294 mOs-
mol/L, within the pediatric reference range [17]. Of note,
isotonic Plasma-Lyte has different naming conventions
around the globe and hence different publications may
refer to Plasmalyte A, Plasmalyte, or Plasmalyte 148. In
the Unites States, there are 2 naming formulations which
are identical in ionic composition but which differ in solu-
tion pH: Plasma-Lyte A (used here) which has a pH of 7.4
and Plasma-lyte 148 which has a pH of 5.5.
Plasma-Lyte A has not previously been studied spe-
cifically in the pediatric population. In addition to the
physiologic chloride level, PLA contains acetate and
gluconate, which serve as buffering agents. It may be
preferred for children with AGE because it replaces water
and electrolytes lost due to diarrhea and vomiting as well
as bicarbonate lost in stool. PLA has the potential to re-
verse the acidosis that may contribute to the physical
symptoms of nausea, vomiting, diarrhea, and abdominal
pain [18, 19].
The hypothesis of this study was that PLA would be
superior to 0.9 % NaCl in improvement of 4-h bicarbon-
ate level and result in faster resolution of clinical signs
and symptoms in children with AGE and dehydration.
Methods
This prospective, randomized, triple-blind, company-
sponsored, active-controlled study was conducted at 8
pediatric emergency departments (ED) in the US and
Canada (NCT#01234883). Institutional ethics approval was
obtained from each institution (Additional file 1: Table S1),
and written informed consent was obtained from the par-
ent/legal guardian of all children before randomization.
Safety data were periodically monitored by an independent
consultant (pediatric nephrologist, SLG) who was not in-
volved in patient recruitment or management.
Patients ≥6 months to <11 years of age were eligible
for enrollment if they presented to the ED with moderate-
to-severe dehydration due to AGE, defined as ≥3 episodes
of diarrhea or nonbilious vomiting within the previous
24 h and a Gorelick dehydration score ≥4 [20]. Screened
patients had blood drawn for serum chemistry. A preran-
domization fluid bolus of ≤20 mL/kg in the 4 h prior to
enrollment was permitted. Exclusion criteria included
AGE that did not require IVT per clinicians’ judgment,
chronic health conditions such as renal failure affecting
the ability to tolerate fluids or those that result in electro-
lyte abnormalities, or the use of prohibited medications
(eg, antacids/anti-diarrhea or systemic corticosteroids within
24 or 72 h prior to presentation, respectively).
During the prestudy period, all patients received routine
care, and oral rehydration therapy and IVT per clinician
judgment. Screening included review of inclusion/exclu-
sion criteria, complete medical history and physical exam,
Gorelick score, abdominal pain assessment, and assess-
ment of volume and type of prestudy IVT.
Concealed treatment allocation was via an Interactive
Voice Recognition System/Interactive Web-based System.
Eligible patients were randomly assigned in a 1:1 ratio
to receive concealed bolus therapy with PLA (Multiple
Electrolyte Injection, Type 1) or 0.9 % NaCl. Following
randomization, hour 0 was defined as the beginning of
infusion of the first bolus of blinded study treatment.
Patients were assessed at baseline, hour 4 (±1), and 48 ±
6 h. The study treatment period was for up to 8 h. If the
patient continued to require IVT beyond the study treat-
ment period, the clinician ordered standard-of-care rehy-
dration IVT. The safety follow-up period was defined
from the end of the last blinded study bolus to 48 ± 6 h.
The protocol recommended 20 mL/kg for the first study
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treatment IV bolus, but the ordered dose was left to pro-
vider discretion [21].
The primary outcome was the change in venous serum
bicarbonate, as measure by total carbon dioxide by clin-
ical chemistry automated analyzers via local laboratories,
between baseline (hour 0) and hour 4. Secondary out-
comes included assessments of the Gorelick score; the
Baxter Animated Retching Face (BARF) [22] score for
nausea/vomiting; pain (FLACC scale for ages six months
to three years, FACES scale for ages 3–11 years); volume
and duration of IVT; time to clinical rehydration, and
length of stay in the ED. Safety assessments included
physical examinations, laboratory assessments, and any
reported or observed adverse events (AEs). At the safety
follow-up, information was obtained regarding AEs, un-
planned return visits, and hospital admission.
The intent-to-treat (ITT) population included all patients
who were randomized to receive study treatment and was
used to assess safety. For the primary and secondary out-
comes, a modified intent-to-treat (mITT) analysis was used
to focus on only those patients with a baseline serum bicar-
bonate level ≤22 mEq/L. This was necessary in order to
allow clinicians to initiate the first study treatment bolus
per standard of care prior to receipt of initial laboratory
test results. However, only patients with baseline serum
bicarbonate level ≤22 mEq/L continued study treatment
in 10-to-20 mL/kg allotments until clinical rehydration
was achieved or hour 8 transpired, whichever occurred
first and was considered the “end of study” treatment. En-
rolled patients with baseline bicarbonate >22 mEq/L had
the study infusion stopped and were considered “early
treatment release (ETR).” They did not undergo 4-h la-
boratory testing but were followed for safety parameters.
Sample size determination was made assuming a 25 %
coefficient of variation and a 15 % difference between
PLA and 0.9 % NaCl for serum bicarbonate level, follow-
ing a log-normal distribution. A sample size of 80 evalu-
able mITT patients (40 per treatment group) had a power
of 80 % to detect such a difference with a 1-sided alpha of
0.05. Planned enrollment for this study was approximately
112 subjects (56 subjects per treatment group to ensure
40 evaluable mITT subjects per treatment group), with an
estimated 30 % attrition rate. The superiority of PLA in
maintaining the baseline serum bicarbonate levels was
established if the one-sided 95 % lower limit of the change
from hour 0 to hour 4 geometric mean ratio of test/con-
trol was greater than one. Stratified analyses by age range
and severity of baseline serum bicarbonate level for the
primary outcome were planned a priori. For continuous
efficacy and safety variables, descriptive summary statistics
were provided by treatment group and time, whereas
between-treatment comparisons at the post-baseline visits
were performed with respect to difference or geometric
mean ratio from baseline. All data are reported, but
no statistical comparisons were performed for groups
with <10 subjects. SAS procedures MIXED, GENMOD,
and LOGISTIC (SAS OnlineDoc®, SAS Institute Inc., Cary,
NC) were used to carry out all analyses. No interim ana-
lyses were planned or performed.
Results
Patient disposition is shown in Fig. 1. The study enroll-
ment period was from January 20, 2011, through February
4, 2013, during which approximately 2,669 patients were
prescreened for study inclusion. The exact number of
patients seen is an estimate, due to different screening
Fig. 1 Patient disposition
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processes between the centers. The study was stopped
early due to slow recruitment after 100 patients were en-
rolled with 77 evaluable mITT subjects. The ITT group was
formed by 100 patients who were randomized to receive ei-
ther PLA (n = 51) or 0.9 % NaCl (n = 49). ETR occurred in
23 patients due to baseline bicarbonate >22 mEq/L. There
were 77 patients (PLA: 39; 0.9 % NaCl: 38) in the mITT
group for assessment of the primary outcome.
Pre-study Treatment Period Comparison
Baseline comparison of the mITT treatment groups is
presented in Table 1. Of note, patients in the PLA group
were older. Both groups exhibited similar Gorelick dehy-
dration scores, as well as similar FLACC, FACES, and
BARF scores. In addition, both groups had similar weight-
based fluid administration prior to receipt of study fluid
(PLA: 17.98 ± 11.17 ml/kg vs 0.9 % NaCl: 15.38 ± 6.55 ml/
kg; Additional file 1: Table S2).
Treatment and outcomes
There were no significant differences in volume, duration
of fluid administration, or maintenance IVT between
groups. The number of boluses was 1.9 for both groups,
dose of study treatment was 38.4 mL/kg vs 39.6 mL/kg,
duration of administration was 104.3 min vs 93.7 min and
maintenance fluid was 12.2 vs 12.3 mL/kg PLA vs 0.9 %
NaCl respectively, all P > .05. Twelve patients in the PLA
group received concomitant maintenance IV fluid vs 11 in
the 0.9 % NaCl group.
Outcome comparisons between the two groups are
presented in Table 2. Patients receiving PLA demonstrated
significantly greater increase in serum bicarbonate levels
from baseline to hour 4 compared with patients receiving
0.9 % NaCl. When stratified by bicarbonate level severity,
PLA showed superiority over 0.9 % NaCl treatment for
bicarbonate ranges ≥12 to 16. Although PLA patients
in the >16 to 22 mEq/L bicarbonate range had a statis-
tically significant increase in serum bicarbonate levels
(P < .05), the increase in the PLA group was not signifi-
cantly different from the 0.9 % NaCl group (P = .11)
for this bicarbonate range. None of the patients re-
ceiving 0.9 % NaCl had baseline serum bicarbonate
level <12 mEq/L. The three patients with severe acid-
osis who received PLA demonstrated a mean improve-
ment in serum bicarbonate level from 9.3 ± 0.6 mEq/L
to 14.3 ± 4.2 mEq/L.
Comparison by age strata demonstrated PLA superior-
ity for the >2 years to ≤5 years age range (mean 17.16 to
18.31; P < .05). Although the >5 years to <11 years age
range had a significant increase in serum bicarbonate level
for PLA patients (P < .05), superiority over 0.9 % NaCl was
not calculated due to the small number of older subjects
in the 0.9 % NaCl group. Patients receiving PLA dem-
onstrated significant improvements in clinical status as
measured by the hour 2 Gorelick score and FLACC
pain scales. Patients in the PLA group had improve-
ment in BARF scores from baseline to hour 2 (mean
change −3.6 ± 5.1; P = .005) and hour 4 (mean change
−4.8 ± 3.97; P = .005). Patients in the 0.9 % NaCl group
did not show similar BARF score improvements at hour
2 (mean change−2.1 ± 4.0; P = .08) but did at hour 4 (mean
change −2.9 ± 3.88; P = .02). However, between-group
BARF scores were not significant. No other differences in
secondary outcome measures were observed.
Safety outcomes
The shift in potassium and sodium levels from baseline
to hour 4 is presented in Figs. 2 and 3. There were no
episodes of hyponatremia (<130 mEq/L) or hypernatre-
mia (>155 mEq/L) in either group. Some patients in
each group presented with hyponatremia that was also
documented at hour 4 (PLA: 8/13; 0.9 % NaCl: 4/8), and
one patient in each group developed mild hyponatremia
(131–135 mEq/L). Hypokalemia (<3.5 mEq/L for ages
≥6 months to ≤2 years and <3.0 mEq/L for ages 2–11
years) and hyperkalemia (>5.6 mEq/L for ages ≥6 months
Table 1 Baseline clinical and biochemical characteristics
(mITT population)
Plasma-Lyte A 0.9 % NaCl
n = 39 n = 38
Age*, months, mean 45.9 34.2
Age group, n (%) ≥6 months to ≤2 years 8 (21) 20 (53)
>2 to ≤5 years 21 (54) 11 (29)
>5 to <11 years 10 (26) 7 (18)
Weight*, kg 15.8 ± 5.18 13.5 ± 6.80
Vomiting episodes 8.9 ± 8.53 6.1 ± 5.92
Diarrhea episodes 4.8 ± 4.77 6.8 ± 6.77
Capillary refill time*, seconds 3.3 ± 0.50 2.8 ± 0.26
Bicarbonate, mEq/L 16.9 ± 3.51 17.8 ± 2.82
Sodium, mEq/L 137.0 ± 4.07 136.9 ± 2.93
Potassium, mEq/L 4.4 ± 0.80 4.2 ± 0.67
Chloride, mEq/L 103.0 ± 4.74 103.5 ± 4.19
BUN, mg/dL 16.5 ± 7.17 14.6 ± 6.33
Creatinine*, mg/dL 0.43 ± 0.13 0.37 ± 0.10
Glucose, mg/dL 70.3 ± 21.26 74.4 ± 21.62
Gorelick dehydration scale, median (IQR) 5 (5–6) 5 (5–6)
Ondansetron 36 (92) 29 (76)
All analgesicsa 25 (64) 23 (61)
BUN blood urea nitrogen, IQR interquartile range
All data are presented as mean ± standard deviation unless
otherwise indicated
aAcetaminophen, nonsteroidal anti-inflammatory drugs, and narcotics
administered orally and/or by intravenous infusion
*P <0.05 PLA vs 0.9 % NaCl
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to ≤2 years and >5.5 mEq/L for ages 2–11 years) were
both assessed. Two patients in the PLA group vs 6 in
the 0.9 % NaCl group became hypokalemic at hour 4.
Four patients in the study developed hyperkalemia (PLA:
1/39 vs 0.9 % NaCl: 3/38) by hour 4. All samples showing
hyperkalemia demonstrated hemolysis, all of which were
deemed clinically insignificant by the investigators.
Discussion
This prospective, randomized, triple-blind, multicenter
trial comparing PLA to 0.9 % NaCl in children with de-
hydration secondary to AGE determined that PLA was
superior to 0.9 % NaCl for improving the metabolic acidosis
(change from baseline in bicarbonate of 1.6 mEq/L for PLA
vs 0.0 mEq/L for 0.9 % NaCl) despite comparable initial
Table 2 Primary and secondary outcomes (mITT population)
Plasma-Lyte A 0.9 % NaCl P value
n = 39 n = 38
Bicarbonate <23 mEq/L
Baseline (hour 0) 16.9 ± 3.51 17.8 ± 2.82 .004
Hour 4 18.5 ± 3.74 18.0 ± 3.67
Bicarbonate <12 mEq/L
Baseline (hour 0) (n) 9.3 ± 0.58 (3) – (0) NAb
Hour 4 (n) 14.3 ± 4.16 (3) – (0)
Bicarbonate ≥12–16 mEq/L
Baseline (hour 0) (n) 14.5 ± 1.34 (13) 14.6 ± 1.29 (13) .04
Hour 4 (n) 16.1 ± 2.28 (12) 14.7 ± 2.90 (11)
Bicarbonate >16–22 mEq/L
Baseline (hour 0) (n) 19.23 ± 1.86 (23) 19.51 ± 1.68 (25) .11
Hour 4 (n) 20.35 ± 3.18 (22) 19.53 ± 2.95 (24)
Chloride, mmol/L
Baseline 103.03 ± 4.74 103.53 ± 4.19 <0.001
Hour 4 104.49 ± 3.18 108.51 ± 4.87
Gorelick dehydration scale
Baseline (hour 0) 5.2 ± 0.93 5.3 ± 1.11 .03
Hour 2 2.0 ± 1.45 2.8 ± 1.74
Hour 4 0.81 ± 0.84 1.41 ± 1.08 .08
FLACC pain scale
Baseline (Hour 0) 2.0 ± 1.91 1.7 ± 2.00 .03
Hour 2 0.6 ± 0.98 1.7 ± 2.59
Hour 4 1.44 ± 2.18 0.68 ± 1.35 .15
FACES pain scale
Baseline (Hour 0) 2.3 ± 1.86 3.2 ± 1.90 .31
Hour 2 1.1 ± 1.55 1.9 ± 1.60
Hour 4 0.37 ± 0.60 1.11 ± 1.54 NA
BARF Scale
Baseline (Hour 0) 5.10 ± 4.02 4.43 ± 3.86 .27
Hour 2 1.5 ± 3.10 2.00 ± 2.58 .55
Hour 4 0.3 ± 0.98 1.23 ± 2.24 .12
Time to Rehydrationa, h 6.1 ± 1.75 7.0 ± 2.7 .13
Hospitalized, n (%) 12 (31) 11 (29) .86
BARF, Baxter animated retching faces; FLACC, face, legs, activity, cry, consolability pain assessment scale for children
All data are presented as mean ± standard deviation unless otherwise indicated
aRehydration was defined as the time the clinician determined no further bolus fluid therapy was indicated
bNot available due to sample size (n <10)
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serum bicarbonate levels and comparable volumes of IVT.
In addition to acidosis, pain as assessed by the FLACC
scale, and dehydration score significantly improved at hour
2 in patients receiving PLA. The clinical significance of the
improved dehydration scores at hour 2 is unclear as the
dehydration scores were not significantly improved at
hour 4 in patients receiving PLA. It may be that once
the intravascular fluids redistributed, the clinical picture
was similar between the two treatment groups. Importantly,
neither PLA nor 0.9 % NaCl induced significant hyponatre-
mia or hyperkalemia. In fact, the frequency of conversion
to abnormal laboratory values was similar between groups.
Although randomization was performed at the center
level, the distribution of the children’s age and weight
Fig. 2 Change in sodium levels from baseline to hour 4
Fig. 3 Change in potassium levels from baseline to hour 4
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was dissimilar between groups, precluding some test
comparisons due to small sample size. However, there
were no differences in weight-based rehydration volumes
or time despite baseline differences in age and capillary
refill. Age stratification demonstrated a similar treatment
effect across age groups.
We tested serum bicarbonate as the primary outcome of
this study based on evidence suggesting that dehydration
severity is related to bicarbonate [23]. Low serum bicar-
bonate levels are the most common electrolyte abnormal-
ity occurring in children with AGE, and dehydration
severity has been found to be related to the bicarbonate
concentration on admission [24, 25]. Bicarbonate is also
the electrolyte most likely to alter care [25] in that it corre-
lates with extended stay, admission to the observation
unit, and administration of more IVT. Bicarbonate is a
quantifiable, objective determinant, thus it is ideal for stat-
istical power determination [9]. The European Society for
Paediatric Gastroenterology, Hepatology, and Nutrition/
European Society for Paediatric Infectious Diseases
recommends that serum bicarbonate laboratory tests
be considered in dehydrated children if IVT is started
[26]. These guidelines also recommend rapid rehydration
with 20 mL/kg/h of 0.9 % saline solution for 2 to 4 h.
The high level of chloride in 0.9 % NaCl is known to
be associated with hyperchloremic metabolic acidosis.
Therefore, it is not surprising that despite its ability to
rehydrate in this study, 0.9 % NaCl did not improve
metabolic acidosis. Our study determined that correcting
acidosis and fluid status was associated with clinically
relevant outcomes of significant improvement in dehy-
dration scores and abdominal pain. In addition, although
the study was not powered to detect a difference in time
to rehydration, the data suggest that there may be a clin-
ically meaningful difference of nearly 1 h (P = .13) and
may warrant further study with a larger sample.
Interestingly, 0.9 % NaCl induced hyperchloremia with-
out an associated change in bicarbonate. This finding is in
contrast to studies in children with severe AGE [12] where
it increased bicarbonate, and in contrast to adult studies
that show when 0.9 % NaCl is used as a resuscitative fluid,
it generally decreases serum bicarbonate [27–29].
When 0.9 % NaCl is used to treat children with acute
diarrhea and severe dehydration, pH may decrease des-
pite improvement in clinical signs of rehydration [30] In
the present study the finding that 0.9 % NaCl caused a
significant increase in serum chloride levels suggests that
0.9 % NaCl may exacerbate AGE acidosis via an ensuing
non-anion gap metabolic acidosis, due to a rapid rise in
serum chloride levels relative to sodium [29].
The majority of children were rehydrated with ap-
proximately 40 mL/kg of treatment fluid. Although we
allowed treatment for up to 8 h, most were rehydrated
with bolus infusions of less than 2 h and independent of
IVT type, approximately one-third in each group needed
observation/inpatient admission for continued hydration.
We also found that electrolyte abnormalities post-
treatment were similar between the two treatment groups,
alleviating concerns of using a solution that contains a
lower sodium concentration than 0.9 % NaCl and that
contains potassium.
While common practice does not introduce potassium
until urine output is observed, this study supports the
safe use of a fluid containing physiologic amounts of
potassium. In fact, the amount of potassium delivered
by PLA treatment during the study is surprisingly
small–PLA contains 5 mEq/L of potassium. The average
child in the PLA group weighed approximately 16 kg. At
40 mL/kg, the average child received a total of 3.2 mEq of
potassium via PLA, which is equivalent to about one-third
of a banana.
The strengths of this study were its randomization,
effective blinding, clinical equipoise, and multicenter
design. Limitations were its relatively small sample size
and the resultant inability to detect some clinically import-
ant secondary outcomes. Although the primary objective
was achieved despite a lower-than-planned enrollment,
not meeting planned enrollment may have impaired our
ability to detect some of the secondary outcomes. More-
over, although the random assignment was not similar in
terms of age or weight, the weight-based volumes deliv-
ered were similar. The planned evaluation of the impact of
PLA by severity of baseline acidosis as measured by the
bicarbonate strata was limited by the lack of severely
dehydrated children in the 0.9 % NaCl group.
Conclusion
This study adds new information for the treatment of
AGE-induced dehydration. PLA is an appropriate alterna-
tive to 0.9 % NaCl because it provides the necessary water
and electrolyte replacement, and as an alkalinizing agent
it may ameliorate the clinical sequelae of AGE-induced
acidosis. Both PLA and 0.9 % NaCl were effective and
well tolerated and had similar safety profiles. Plasma-Lyte A
was more effective than 0.9 % NaCl at correcting acidosis,
in particular in patients with moderate acidosis on admis-
sion, and led to improved clinical findings of dehydration.
Additional file
Additional file 1: Table S1. Ethics Committees. Table S2. IVF bolus
during screening and safety follow-up visits (mITT population). (DOCX 15 kb)
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